Ozon Pharmaceuticals ' IFRS net profit for 3 months of 2025 was ₽0.993 billion, an increase of 28% compared to ₽0.776 billion in the previous year. Revenue increased by 45.2% to ₽6.855 billion from ₽4.722 billion a year earlier.

Shareholders of Ozon Pharmaceuticals approved dividends for 2024 in the amount of ₽0.26 per ordinary share. The last day of purchase of securities to receive dividends is June 4, 2025. Dividend yield may amount to 0.54%.

Ozon Pharmaceuticals Group at the end of April introduced a new over-the-counter drug Safiston® Neo on the Russian pharmaceutical market. Combined analgesic based on acetylsalicylic acid, caffeine and paracetamol is intended for the treatment of mild to moderate pain syndrome, as well as fever reduction in flu and other acute respiratory diseases. To date, t...

Ozone Pharmaceuticals' RAS net profit for 3 months of 2025 amounted to ₽0.429 billion, down 2.8 times from ₽1.2 billion in the previous year. Revenue fell 41.5% to ₽0.708 billion against ₽1.21 billion a year earlier.